{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:26:20Z","timestamp":1749644780302},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s11899-012-0146-x","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T07:19:41Z","timestamp":1355901581000},"page":"7-13","source":"Crossref","is-referenced-by-count":9,"title":["Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"8","author":[{"given":"Christine I.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"146_CR1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"276","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowsan G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial. Lancet. 2010;276:1164\u201374.","journal-title":"Lancet"},{"key":"146_CR2","unstructured":"Chanan-Khan A. Pro-apoptotic effect of lenalidomide in patients with chronic lymphocytic leukemia is possibly mediated through interruption of phosphatidylinositol pathway. Presented at the 48rd American Society of Hematology Annual Conference [abstract 2102]. Orlando, USA, Dec 9\u201312, 2006."},{"key":"146_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson S, et al. Orally administered lenalidomide is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69:56\u201363.","journal-title":"Microvasc Res"},{"key":"146_CR4","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","volume":"104","author":"A Pellagatti","year":"2007","unstructured":"Pellagatti A, Jadersten M, Forsblom A, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007;104:11406\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"146_CR5","first-page":"635","volume":"5","author":"C Mitsiades","year":"2004","unstructured":"Mitsiades C, Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs. 2004;5:635\u201347.","journal-title":"Curr Opin Investig Drugs"},{"key":"146_CR6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"L Corral","year":"1993","unstructured":"Corral L, Haslett P, Muller F, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide anlaogues that are potent inhibitors of TNF-alpha. J Immunol. 1993;163:380\u20136.","journal-title":"J Immunol"},{"key":"146_CR7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","volume":"22","author":"I Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab M, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22:1925\u201332.","journal-title":"Leukemia"},{"key":"146_CR8","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Braggio E, Shi C-X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771\u20139.","journal-title":"Blood"},{"key":"146_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","volume":"155","author":"A Chanan-Khan","year":"2011","unstructured":"Chanan-Khan A, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-inducded tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011;155:457\u201367.","journal-title":"Br J Haematol"},{"key":"146_CR10","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","volume":"115","author":"R Lapalombella","year":"2010","unstructured":"Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway. Blood. 2010;115:2619\u201329.","journal-title":"Blood"},{"key":"146_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Ramsay A, Clear A, Fatah R, Gribben J. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood. 2012; [Epub ahead of print]. The authors of this study have previously demonstrated tumor-cell induced T cell synapse dysfunction in CLL. This study identifies that lenalidomide is able to reverse this dysfunction by down-regulating the expression of inhibitory ligands on tumor cells and their receptors on T cells. This provides further insight into lenalidomide\u2019s mechanism of action in CLL.","DOI":"10.1182\/blood-2012-02-411678"},{"key":"146_CR12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3324\/haematol.2009.009274","volume":"94","author":"A Ramsay","year":"2009","unstructured":"Ramsay A, Gribben J. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica. 2009;94:1198\u2013202.","journal-title":"Haematologica"},{"key":"146_CR13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1470-2045(06)70723-9","volume":"7","author":"A Chanan-Khan","year":"2006","unstructured":"Chanan-Khan A, Porter C. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006;7:480\u20138.","journal-title":"Lancet Oncol"},{"key":"146_CR14","first-page":"2427","volume":"118","author":"A Ramsay","year":"2008","unstructured":"Ramsay A, Johnson A, Lee A, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immuomodulating drug. J Clin Invest. 2008;118:2427\u201337.","journal-title":"J Clin Invest"},{"key":"146_CR15","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1002\/cncr.25983","volume":"117","author":"B-N Lee","year":"2011","unstructured":"Lee B-N, Gao H, Cohen E, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patietns with chronic lymphocytic leukemia. Cancer. 2011;117:3999\u20134008.","journal-title":"Cancer"},{"key":"146_CR16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2141.2009.08014.x","volume":"148","author":"I Idler","year":"2009","unstructured":"Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leuaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol. 2009;148:948\u201363.","journal-title":"Br J Haematol"},{"key":"146_CR17","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","volume":"94","author":"G Aue","year":"2009","unstructured":"Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94:1266\u201377.","journal-title":"Haematologica"},{"key":"146_CR18","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","volume":"24","author":"A Chanan-Khan","year":"2006","unstructured":"Chanan-Khan A, Killer K, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343\u20139.","journal-title":"J Clin Oncol"},{"key":"146_CR19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","volume":"29","author":"C Chen","year":"2011","unstructured":"Chen C, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:1175\u201381.","journal-title":"J Clin Oncol"},{"key":"146_CR20","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","volume":"111","author":"A Ferrajoli","year":"2008","unstructured":"Ferrajoli A, Lee B-N, Schlette E, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291\u20137.","journal-title":"Blood"},{"key":"146_CR21","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2007.14.2141","volume":"25","author":"L Moutouh-de Parseval","year":"2007","unstructured":"Moutouh-de Parseval L, Weiss L, DeLap R, et al. Tumor lysis syndrome\/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5047.","journal-title":"J Clin Oncol"},{"key":"146_CR22","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","volume":"118","author":"X Badoux","year":"2011","unstructured":"\u2022 Badoux X, Keating M, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118:3489\u201398. This Phase 2 study of single agent lenalidomide in previously untreated CLL demonstrated that longer therapy and higher doses of lenalidomide are associated with a greater chance of response. This study confirmed the safety of initial continuous dosing of 5\u00a0mg daily.","journal-title":"Blood"},{"key":"146_CR23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10428194.2011.618232","volume":"53","author":"C-M Wendtner","year":"2012","unstructured":"\u2022 Wendtner C-M, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymph. 2012;53:417\u201323. This Phase 1 study helped to establish the safety of lenalidomide dosing and scheduling, starting at a 5\u00a0mg daily dose, escalating monthly by 5\u00a0mg daily. This starting dose and escalation rate has been adopted in subsequent clinical trials.","journal-title":"Leuk Lymph"},{"key":"146_CR24","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","volume":"26","author":"L Andritsos","year":"2008","unstructured":"Andritsos L, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519\u201325.","journal-title":"J Clin Oncol"},{"key":"146_CR25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ajh.22114","volume":"86","author":"G Aue","year":"2011","unstructured":"Aue G, Lozier J, Tian X, et al. Inflammation, TNF\u03b1 and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol. 2011;86:835\u201340.","journal-title":"Am J Hematol"},{"key":"146_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428190903406806","volume":"51","author":"T Sher","year":"2010","unstructured":"Sher T, Miller K, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymph. 2010;51:85\u20138.","journal-title":"Leuk Lymph"},{"key":"146_CR27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","volume":"117","author":"A Chanan-Khan","year":"2011","unstructured":"Chanan-Khan A, Miller K, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127\u201335.","journal-title":"Cancer"},{"key":"146_CR28","doi-asserted-by":"crossref","unstructured":"Aue G, Soto S, Valdez J, et al. A phase II trial of pulse dosing lenalidomide: 3\u00a0weeks on 3\u00a0weeks off in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract 3427]. Presented at the 51st American Society of Hematology Annual Conference. New Orleans, USA, Dec 5\u20138, 2009.","DOI":"10.1182\/blood.V114.22.3427.3427"},{"key":"146_CR29","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","volume":"112","author":"R Lapalombella","year":"2008","unstructured":"Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112:5180\u20139.","journal-title":"Blood"},{"key":"146_CR30","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650\u20137.","journal-title":"Clin Cancer Res"},{"key":"146_CR31","doi-asserted-by":"crossref","unstructured":"Badoux X, Keating M, O\u2019Brien S, et al. Final analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract 980]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011.","DOI":"10.1182\/blood.V118.21.980.980"},{"key":"146_CR32","unstructured":"James D, Brown J, Werner L, et al. Lenalidomide and rituximab for the initial treatment of patinets with chronic lymphocytic leukemia (CLL)\u2014A multicenter study of the CLL Research Consortium [abstract 291]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011."},{"key":"146_CR33","unstructured":"Ferrajoli A, O\u2019Brien S, Wierda W, et al. Combination therapy with ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): Results of a phase II trial [abstract 1788]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011"},{"key":"146_CR34","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/leu.2010.199","volume":"24","author":"J Brown","year":"2010","unstructured":"Brown J, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL\/SLL. Leukemia. 2010;24:1972\u20135.","journal-title":"Leukemia"},{"key":"146_CR35","unstructured":"Flinn I, Berdeja J, KWaselenko J, et al. Preliminary results from a phase I\/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL) [abstract 2461]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011."},{"key":"146_CR36","doi-asserted-by":"crossref","unstructured":"Egle A, Steurer M, Gassner F, et al. A combination of fludarabine\/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I\/II Study, clinical and exploratory analyses of induction results [abstract 292]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011.","DOI":"10.1182\/blood.V118.21.292.292"},{"key":"146_CR37","unstructured":"Shanafelt T, Tun H, Hanson C, et al. Lenalidomide consolidation appears to prolong time to retreatment after first-line chemoimmunotheray for patients with previously untreated CLL [abstract 3899]. Presented at the 53rd American Society of Hematology Annual Conference. San Diego, USA, Dec 10\u201313, 2011."},{"key":"146_CR38","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","volume":"117","author":"S Herman","year":"2011","unstructured":"Herman S, Lapalombella R, Gordon A, et al. The role of phosphatidylinositol 3-kinase-\u03b4 in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117:4323\u20137.","journal-title":"Blood"},{"key":"146_CR39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2141.2008.07548.x","volume":"144","author":"R Lapalombella","year":"2009","unstructured":"Lapalombella R, Gowda A, Joshi T, et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukemia. Br J Haematol. 2009;144:848\u201355.","journal-title":"Br J Haematol"},{"key":"146_CR40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2141.2011.08984.x","volume":"157","author":"A Masood","year":"2012","unstructured":"Masood A, Chitta K, Paulus A, et al. Downregulation of BCL2 by AT-101 enhances teh antileukemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012;157:59\u201366.","journal-title":"Br J Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0146-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0146-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0146-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T22:23:30Z","timestamp":1687904610000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0146-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0146-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}